Verso (VRS) Forms $18.00 Double Top; Biogen Inc. (BIIB) Had 24 Bullish Analysts

Verso Corporation (VRS) formed double top with $19.62 target or 9.00% above today’s $18.00 share price. Verso Corporation (VRS) has $620.37 million valuation. The stock increased 1.32% or $0.23 during the last trading session, reaching $18. About 787,657 shares traded or 47.10% up from the average. Verso Corporation (NYSE:VRS) has 0.00% since March 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 24 have Buy rating, 0 Sell and 9 Hold. Therefore 73% are positive. Biogen Idec Inc. had 117 analyst reports since July 23, 2015 according to SRatingsIntel. As per Wednesday, November 8, the company rating was initiated by Oppenheimer. The firm earned “Hold” rating on Wednesday, January 24 by Canaccord Genuity. H.C. Wainwright maintained Biogen Inc. (NASDAQ:BIIB) on Thursday, October 22 with “Buy” rating. The company was maintained on Tuesday, July 25 by Stifel Nicolaus. Goldman Sachs upgraded Biogen Inc. (NASDAQ:BIIB) on Wednesday, July 26 to “Buy” rating. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Strong-Buy”. The stock has “Overweight” rating by Morgan Stanley on Thursday, October 5. The firm earned “Buy” rating on Monday, November 27 by BMO Capital Markets. Mizuho initiated the stock with “Buy” rating in Tuesday, November 8 report. Mizuho maintained the shares of BIIB in report on Sunday, October 15 with “Hold” rating. See Biogen Inc. (NASDAQ:BIIB) latest ratings:

05/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $403 New Target: $393 Maintain
02/03/2018 Broker: Guggenheim Rating: Buy New Target: $400.0 Maintain
02/03/2018 Broker: RBC Capital Markets Rating: Hold New Target: $330.0 Maintain
02/03/2018 Broker: BMO Capital Markets Rating: Buy New Target: $393.0 Maintain
16/02/2018 Broker: Argus Research Old Rating: Buy New Rating: Hold Downgrade
15/02/2018 Broker: William Blair Rating: Buy
07/02/2018 Broker: Credit Suisse Rating: Buy New Target: $384.0 Upgrade
04/02/2018 Broker: Mizuho Rating: Buy New Target: $433.0 Maintain
31/01/2018 Broker: UBS Rating: Buy New Target: $410.0 Upgrade
25/01/2018 Broker: Credit Suisse Rating: Hold New Target: $385.0 Downgrade

Since January 9, 2018, it had 0 insider buys, and 5 sales for $2.87 million activity. 5,832 Biogen Inc. (NASDAQ:BIIB) shares with value of $1.92M were sold by PANGIA ROBERT W. $266,444 worth of stock was sold by Sandrock Alfred on Friday, February 23.

Investors sentiment increased to 1.17 in Q3 2017. Its up 0.04, from 1.13 in 2017Q2. It increased, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. Hsbc Plc reported 345,740 shares. Raymond James Advsr invested 0.05% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Bedell Frazier Investment Counseling Ltd Liability Corp reported 25,554 shares. Cohen Steers owns 38,695 shares for 0.03% of their portfolio. 970 were accumulated by Holderness Invs Co. Sandy Spring Bancorporation reported 164 shares stake. Toronto Dominion National Bank & Trust holds 0.08% or 80,414 shares. Boyer Corporon Wealth Mngmt Lc invested in 0.1% or 782 shares. Of Vermont has 3,181 shares. Mairs & holds 1,053 shares. The Virginia-based Bb&T Ltd Limited Liability Company has invested 0.06% in Biogen Inc. (NASDAQ:BIIB). Cadence Cap Management Ltd stated it has 6,417 shares. Guardian Limited Partnership invested in 869 shares. Tributary Cap Lc accumulated 0.05% or 2,000 shares. 75,741 were accumulated by Bnp Paribas Asset Mgmt.

The stock decreased 0.69% or $1.9 during the last trading session, reaching $275.39. About 462,894 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since March 22, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $58.26 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 23.1 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

Among 2 analysts covering Verso Corporation (NYSE:VRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Verso Corporation has $25 highest and $11.25 lowest target. $22’s average target is 22.22% above currents $18 stock price. Verso Corporation had 8 analyst reports since July 27, 2016 according to SRatingsIntel. On Friday, March 9 the stock rating was maintained by FBR Capital with “Buy”. The firm earned “Strong Buy” rating on Wednesday, October 18 by BWS Financial. The rating was maintained by FBR Capital with “Buy” on Wednesday, December 20. The rating was initiated by BWS Financial with “Buy” on Wednesday, July 27. BWS Financial maintained the stock with “Strong Buy” rating in Friday, November 17 report. On Friday, February 16 the stock rating was upgraded by FBR Capital to “Buy”.